WWTR1 and choroidal neovascularization: VP is a benzoporphyrin derivative that inhibits the nuclear YAP/TAZ-TEAD interaction to suppress the transcriptional activity, which is an FDA-approved drug for the treatment of choroidal neovascularization and is commonly used as a YAP/TAZ inhibitor [41, 42].